<DOC>
	<DOCNO>NCT02310906</DOCNO>
	<brief_summary>This first-in-human , multiple-dose 2-part study ass safety , tolerability , efficacy , pharmacokinetics SRP-4053 Duchenne muscular dystrophy ( DMD ) patient deletion amenable exon 53 skipping .</brief_summary>
	<brief_title>Phase I/II Study SRP-4053 DMD Patients</brief_title>
	<detailed_description>Part 1 : Randomized , placebo-controlled dose-titration ass safety , tolerability pharmacokinetics 4 dose level SRP-4053 genotypically-confirmed DMD patient deletion amenable exon 53 skip . Part 2 : Open-label evaluation SRP-4053 patient Part 1 , along newly enrol DMD patient deletion amenable exon 53 skipping , compare untreated control DMD patient deletion amenable exon 53 skip . Safety , include adverse event monitoring routine laboratory assessment , follow ongoing basis patient . Clinical efficacy , include functional test six-minute walk test ( 6MWT ) , assess regularly schedule study visit . Patients treat group undergo one baseline one follow-up muscle biopsy . Patients untreated control group undergo biopsy follow abbreviate schedule study assessment .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Diagnosed DMD , genotypically confirm . Intact right leave biceps muscle alternative upper arm muscle group . Stable pulmonary cardiac function . Minimum performance 6MWT , North Star Ambulatory Assessment , rise ( Gowers ) test specify study protocol . On stable dose corticosteroid least 6 month . Previous treatment experimental agent BMN195 ( SMT C1100 ) PRO053 . Current previous treatment experimental treatment within 12 week prior study entry . Major surgery within last 3 month . Presence clinically significant illness . Major change physical therapy regime within last 3 month . Other inclusion exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Duchenne muscular dystrophy</keyword>
	<keyword>Exon Skipping</keyword>
</DOC>